This is clinically important because ENT1 and ENT2 are involved in the uptake of the COVID-19 drugs - remdesivir and molnupiravir, making this uptake pathway potentially liable to dysregulation with SARS-CoV-2 infection and may partly explain the limited and variable clinical efficacy observed for remdesivir (Johnson, 2022). The gene discussed is SLC29A2; the disease is COVID-19.